美國學(xué)者的一項研究表明，在糖尿病診斷持續時(shí)間較長(cháng)以及現時(shí)應用胰島素的2型糖尿病患者中癌癥負擔增高。論文于2013年1月8日在線(xiàn)發(fā)表于《糖尿病護理》（Diabetes Care）。

此項研究從2009年行為危險因素監測系統參與者中納入25,964例患者；受試者年齡≥18歲，并且均伴有糖尿病診斷。

結果顯示，對潛在混淆因素進(jìn)行校正之后，糖尿病診斷持續越長(cháng)則癌癥患病率越高。在診斷為2型糖尿病的成人中，糖尿病診斷時(shí)間≥15年的男、女性患者在各部位癌癥估計患病率方面明顯高于診斷時(shí)間<15年者。在男、女性受試者中，現時(shí)胰島素應用者的各部位癌癥估計患病率均約為未應用者的2.3倍。

To estimate the prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes.

We analyzed data from 25,964 adults aged ≥18 years with diagnosed diabetes who participated in the 2009 Behavioral Risk Factor Surveillance System.

After adjustment for potential confounders, we found that the greater the duration of diagnosed diabetes, the higher the prevalence of diagnosed cancers (P < 0.0001 for linear trend). Among adults with diagnosed type 2 diabetes, the prevalence estimate for cancers of all sites was significantly higher among men (adjusted prevalence ratio 1.6 [95% CI 1.3–1.9]) and women (1.8 [1.5–2.1]) who reported being diagnosed with diabetes ≥15 years ago than among those reporting diabetes diagnosis <15 years ago. The prevalence estimate for cancers of all sites was ~1.3 times higher among type 2 diabetic adults who currently used insulin than among those who did not use insulin among both men (1.3 [1.1–1.6]) and women (1.3 [1.1–1.5]).

Our results suggest that there is an increased burden of diagnosed cancer among adults with a longer duration of diagnosed diabetes and among type 2 diabetic adults who currently used insulin.